Trial Profile
A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms PERUSE
- Sponsors Roche
- 02 Jul 2021 Results reporting final safety and efficacy analysis from this trial published in the Annals of Oncology
- 21 Sep 2020 Final results presented at the 45th European Society for Medical Oncology Congress.
- 19 Oct 2019 This trial has been completed in Spain, according to European Clinical Trials Database.